As genetic PDL1 depletion is not currently clinically actionable, we hypothesized that pharmacologic tumor PDL1 depletion could inhibit tumor-intrinsic PDL1 signals to replicate genetic PDL1 depletion effects on DNA damage and sensitize tumors to DNA-damaging agents. The gene discussed is CD274; the disease is neoplasm.